Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maine for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maine only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maine (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

David Benton (NPI 1336346501)

Field	Value
Entity Type	Individual
Organization	David Benton
Address	105 Topsham Fair Mall Rd Unit 1
City	Topsham
State	ME
ZIP	04086
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 29, 2007

Payer Source	Total Paid
Medicare	$2.6M
Medicaid	$0

Key Findings

This provider is effectively an infusion-focused hematology/oncology practice: the top revenue drivers are high-cost injectable oncology and immunotherapy agents (J9271, J9144) plus immune globulin (J1569), which together account for 79.7% of the provider's Medicare revenue. The mix—large volumes of pembrolizumab (J9271) and daratumumab (J9144) with supplemental immune globulin billing—is consistent with a practice organized around regular infusion sessions rather than visit-based procedures alone.

Revenue concentration is high and heavily weighted to two drugs: J9271 accounts for $946K (37.0% of Medicare revenue) and J9144 accounts for $896K (35.0%), with J1569 contributing $196.2K (7.7%). The published precomputation that the top three codes make up 79.7% of Medicare revenue highlights material concentration risk if utilization or payer policy changes affect these specific agents.

Payer mix is effectively single-payer Medicare: total Medicare revenue is $2.6M while there is no Medicaid billing on file. This means the provider’s revenue profile and utilization patterns are driven almost entirely by Medicare-covered patients and reimbursement practices.

Competitive standing by code is mixed: for daratumumab (J9144) the provider ranks #37 of 615 nationally and is in the 94th percentile—characterized in the source as "notably above typical" national volume—indicating an unusually large national-volume footprint for that product. By contrast, pembrolizumab (J9271) ranks #308 of 1841 at the 83th percentile and is labeled "typical, unremarkable volume," suggesting strong but not exceptional national standing for that agent.

Although the practice is drug-centric, E/M activity shows an unusual national profile: 99214 appears as an "extreme outlier, far above typical national volume" at the 98th percentile (rank #9166 of 479517) and generates $98.3K (3.8% of Medicare revenue). This combination—high infusion drug revenue with disproportionately high established-patient E/M coding—suggests a steady outpatient panel managed alongside large infusion throughput.

Other supportive services and infusion administration codes (for example, 96413, 96365, 96401 and related add-ons) appear at typical national volumes and make up relatively small shares of revenue, reflecting that most Medicare dollars here are drug reimbursement rather than administration fees. Lab and basic phlebotomy codes (80053, 85025, 36415) are present at typical volumes and together contribute modestly to revenue, consistent with routine monitoring for oncology patients.

Tenure is long-standing: the NPI was enumerated on 2007-06-29 (~19 years ago), indicating an established provider with nearly two decades of Medicare enrollment history. That longevity supports the interpretation of the billing mix as a stable practice pattern rather than a short-term fluctuation.

From a risk/strategy perspective, the provider’s financial exposure is concentrated in a small set of high-cost drugs (79.7% of Medicare revenue from the top three codes) and entirely tied to Medicare reimbursement since there is no Medicaid activity on file. For payers and network planners this profile signals a specialized oncology infusion provider whose negotiating leverage and utilization impact will be driven largely by daratumumab and pembrolizumab usage patterns.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

59 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	22,000	$40	$946K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	23,580	$40	$896K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	5,450	$40	$196.2K
J0897	Injection, denosumab, 1 mg	10,440	$20	$187.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,090	$90	$98.3K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	20,500	$1	$41K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	350	$90	$31.6K
J1439	Injection, ferric carboxymaltose, 1 mg	26,250	$1	$26.3K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	120	$130	$15.7K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	50	$320	$15.1K

Showing 1–10 of 59

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 59 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maine Distribution

David Benton — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maine

Full comparison — all codes billed, vs. state median

59 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9144	1	10	21,420	$40	$813.5K
J9271	2	10	16,450	$40	$699.2K
J1569	2	10	3,150	$40	$144.9K
J0897	3	20	2,730	$20	$86.4K
J0881	3	10	15,200	$1	$47K
J1439	5	10	24,750	$1	$32.2K
J9217	4	10	120	$130	$27.9K
96413	4	30	170	$100	$20.6K
J1454	7	10	60	$340	$18.3K
J9041	1	10	3,260	$1	$12.2K

Showing 1–10 of 59

Related Providers

Other providers that share a Tax Identification Number (TIN) with David Benton, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mercy Hospital	ME	General Acute Care Hospital	$0	$35.5M
Can Ilyas	ME	Hematology & Oncology Physician	$3.2M	$0
Matthew Dugan	ME	Hematology & Oncology Physician	$1.8M	$0
John Winters	ME	Hematology & Oncology Physician	$1.5M	$0
Maine Center For Cancer Medicine & Blood Disorders, P.A.	ME	Hematology & Oncology Physician	$0	$1.5M
Christian Thomas	ME	Hematology & Oncology Physician	$1.5M	$0
Devon Evans	ME	Hematology & Oncology Physician	$1.5M	$0
Brian Haney	ME	Hematology & Oncology Physician	$1.2M	$0
Yoko Fukuda	NH	Hematology & Oncology Physician	$945K	$0
Jonathan Proulx	NH	Hematology (Internal Medicine) Physician	$725.4K	$0

Nearby Providers

Other providers in the same ZIP code as David Benton, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Chonko Occupational Therapy, LLC	ME	Occupational Therapist	$0	$772.2K
Julia Moukharskaya	ME	Hematology & Oncology Physician	$519.1K	$0
Greater Brunswick Physical Therapy P.A.	ME	Physical Therapist	$0	$511.7K
Town Of Topsham	ME	Land Ambulance	$126.7K	$205.4K
Jose Ventura	ME	Family Medicine Physician	$50.9K	$197.8K
Michael Davis	ME	Family Nurse Practitioner	$109.4K	$0
Cvs State Capital LLC	ME	Pharmacy	$70.5K	$0
David Inger	ME	Family Medicine Physician	$36.6K	$0
Megan Hutcherson	ME	Pediatric Occupational Therapist	$33.7K	$0
Victoria Thieme	ME	Neuromusculoskeletal Medicine & OMM Physician	$24.3K	$7.4K

David Benton — Billing Profile & Reimbursement Data

Sign up for David Benton — Billing Profile & Reimbursement Data policy alerts

David Benton — Billing Profile & Reimbursement Data

Sign up for David Benton — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References